Securing your brand identity requires a direct understanding of how Canadian trademark use rules govern market assets. You must establish documented proof of use Canada demands to protect your registrations against cancellation proceedings and rival disputes. Without clear operational records of commercial activity across your product lines, your entire trademark enforcement strategy faces serious exposure in administrative and judicial forums. Exploring these statutory standards will help you build defensible portfolio procedures that keep your corporate assets safe from unexpected challenges.
-
Ways Canadian Trademark Proof of Use Rules Impact Brand Owners
-
How to Meet Canadian Patent Subject Matter Rules for AI Models
Securing defensible patent protection for artificial intelligence requires a precise approach to statutory thresholds. You must ensure your machine learning patent claims articulate tangible physical interactions rather than abstract mathematical formulas. When you align your technical architecture with the specific nuances of Canadian patent prosecution, you position your core algorithms as patent eligible subject matter. Discover how structured drafting practices can safeguard your technology, prevent costly examination delays, and solidify the commercial value of your intellectual property assets.
-
Surprising Methods to Monetize Your Intellectual Property Assets
You invest heavily in research and development to secure a competitive advantage within your specific industry. Structuring a proactive IP licensing strategy allows you to generate predictable revenue streams from your existing patents and trademarks. Implementing effective patent portfolio management ensures your organization can identify hidden commercial opportunities across different global markets. By exploring these unexpected methods for intellectual property monetization, you can turn passive legal protections into active financial assets.
-
Are Hidden Patent Risks Threatening Your Next Product Launch?
You invest significant financial and technical resources into developing innovative products for your target market. Moving forward without a comprehensive freedom to operate analysis exposes your organization to severe patent infringement risk. Proactive IP risk management allows you to identify existing patents and avoid costly legal disputes long before your official release date arrives. By addressing these hidden barriers early in the development cycle, you can confidently secure your market position and protect your commercial investments.
-
Should You Protect New Software With Patents or Trade Secrets?
When you develop proprietary algorithms, selecting the correct legal framework dictates your long-term commercial success. You must carefully weigh the public disclosure requirements of a formal software patent strategy against the strict internal security demands of trade secret protection. Making this decision requires a deep understanding of intellectual property law to ensure your innovations remain secure and profitable. By aligning your technical goals with sound commercial legal guidance, you can confidently navigate these complex choices and maximize your competitive advantage in the market.
-
How to Protect Your Tech Startup’s IP From Costly Legal Risks
As a tech startup founder, safeguarding your innovative ideas is crucial to maintaining your competitive advantage and avoiding costly legal setbacks. By understanding the essentials of intellectual property protection and implementing a robust IP strategy, you can proactively reduce tech startup legal risks and prevent infringement before it becomes a threat. This article guides you through practical steps to secure your intellectual assets, helping you steer clear of expensive disputes and ensuring your business is positioned for long-term success. Discover how a strategic approach to intellectual property can empower your growth and protect your unique value in the marketplace.
-
How to Safeguard Your Startup’s Ideas With Smart IP Strategies
Are you a startup founder looking to protect your groundbreaking ideas? In our latest post, “How to Safeguard Your Startup’s Ideas With Smart IP Strategies,” you’ll learn essential steps for effective intellectual property protection. We guide you through actionable startup IP strategy tips and offer business legal advice tailored to the unique challenges startups face. Don’t leave your innovations vulnerable—discover how to secure your competitive advantage and avoid costly legal disputes as you grow your business.
-
How Strategic Intellectual Property Planning Supports Long-Term Business Growth
Unlock the full potential of your business with a robust intellectual property strategy tailored for long-term growth. In this insightful article, you will learn how strategic IP planning can protect your innovations, drive business growth, and deliver a competitive edge—especially for Canadian businesses operating in the technology and pharmaceutical sectors. Discover actionable steps to align your IP approach with your commercial goals, safeguard your assets, and thrive in an evolving marketplace. Whether you are looking to expand locally or globally, this guide will help you build a resilient foundation for sustained success.
-
Why Intellectual Property Strategy Matters for Growing Canadian Businesses
Discover why a robust intellectual property strategy is essential for growing Canadian businesses. Whether you are a startup or an established company in Toronto, Hamilton, Kitchener, Waterloo, Ottawa, or elsewhere in Canada, protecting your business IP can be the key to sustainable success. In this post, you will learn how working with a knowledgeable Toronto IP lawyer can help you stay ahead of the competition, secure your innovations, and navigate the complexities of Canadian business law. Empower your business to expand confidently both locally and globally by understanding the value of intellectual property for startups and established enterprises alike.
-
Announcing The New Website.
We are delighted to announce the launch of our new website!
-
New website under construction.
New Website Coming Soon!
We are currently revamping our website. Our new website will be interactive and mobile friendly! Watch this space for updates. Just a few more weeks to go!
-
US Supreme Court upholds "clear and convincing" invalidity standard
Hot off the press... the US Supreme Court has decided i4i v. Microsoft. At a quick glance: s.282 of the US Patent Act requires a party alleging invalidity to show it by "clear and convincing" evidence. Also at a quick glance, this applies whether or not a piece of prior art was considered by the patent examiner.
-
Meanwhile, over in copyright land...
I have been focused on the effect CETA would have on patents and pharmaceuticals. Of course, there's lots of other stuff in CETA, including copyright. Michael Geist has posted a copy of his comments to the Standing Committee on International Trade HERE.
-
Sanofi Pasteur to expand in Toronto
Sanofi Pasteur, which makes vaccines, is planning to expand its operations in Toronto.
-
Norman Siebrasse Canadian patent blog: "Sufficient Description"
Norman Siebrasse of UNB law, whom I've written papers with in the past and I think has all sorts of good things to say about patents, now has his own blog:
-
Federal Court Overrules Supreme Court on Presumption of Validity
Go read the post on this topic at Sufficient Description. It brings up an interesting topic - when courts review the validity of patents, does it have to comply with administrative law principles, or is it its own standard? Professor Siebrasse notes that Gauthier J. in Eli Lilly / cefaclor 2009 FC 991 essentially ruled that Supreme Court musing on this point was wrong, and agrees with Gauthier J.
-
Analysis of Drug R&D spending hits the popular press
I always think its the beginning of the end of the line for an idea or concept when people start publicly making fun of it. So THIS ARTICLE in Slate Magazine about the Light and Warburton study on drug R&D costs is interesting. The article concludes:
-
More on the Light and Warburton article on Drug Costs
I don’t want to be a blogger that leaves negative comments unaddressed in the comments section, so I want to bring up two good comments to my post on the Light and Warburton article.
First – actually, I shouldn’t have said anything about 11% being a high cost of capital. I certainly don’t keep track of what a reasonable cost is. It could be 20%, for all I know ;)
-
Are Pharmaceutical R&D Costs Exaggerated?
Here is a link to a recent paper (pdf) by Donald Light and Rebecca Warburton titled "Demythologizing the high costs of pharmaceutical research", (BioSocieties, February 2011) which systematically critiques the estimates of pharmaceutical-related R&D costs routinely promoted by the research-based pharmaceutical companies. As put by Andre Picard in a recent Globe and Mail article, "Drug R&D costs are less than estimated - so why the high prices?",
-
Actually...
One risk of blogging is that I often think of something just after pressing "Publish Post" ;)